Important Announcement
about Ebola Virus

Reveille E6/E7

Cell Transformation Alert Assay

A Wake Up Call To Pre-Cancer Progression

95% of HPV-positive patients never progress to cervical cancer.
How do you identify the 5% who are beginning the transformation process?1

Prior to transforming to cervical cancer, HPV-infected cells begin to over-express E6 and E7 oncogenes—these genes
inhibit the cells’ normal ability to control growth and metabolism. The result—cell transformation and ultimately cancer.

Pathology, Inc., the West Coast’s leader in Women’s Health testing, is pleased to introduce Reveille™ for the rapid
detection of over-expression of E6 and E7 from ThinPrep® and SurePath™ specimens. Using flow cytometry, individual
intact cells are analyzed for expression levels of the E6 and E7 oncogenes.2

This cutting-edge technology helps identify those high-risk HPV-positive patients who are beginning the transformation
process, often before cellular changes are visible, and for whom more aggressive follow-up is warranted.

Reveille™ detects cells that are over-expressing E6 and E7 oncogenes, the precursor to cellular transformation and carcinoma.

For More Information
For more information please call Client Services 877.922.7284.

1Patterson BK. Human Papillomaviruses. Manual of Clinical Microbiology, 9th edition, 2008: 1601-11.

2 Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gyn Oncol 2011;120:89-93.

3Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature Rev 2007; 7:11-20.

Connect With Us!

© 2014 Pathology, Inc.